Actuate Therapeutics reported a net loss of $13.9 million for the nine months ended September 30, 2026, compared to $17.7 million in the prior year period. The company's cash position decreased significantly to $2.1 million, resulting in a working capital deficit and a stated going concern uncertainty as it continues to fund clinical development of elraglusib.
Actuate Therapeutics received a deficiency notice from Nasdaq because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until April 26, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. This notice follows a separate July 2026 warning regarding the company's failure to meet the minimum market value of listed securities requirement.
Actuate Therapeutics President, CEO and Director Daniel M. Schmitt Buys $50K of Stock
Daniel M. Schmitt, President, CEO and Director, bought 140,844 shares of Actuate Therapeutics, Inc. at $0.355 a share, worth $50K in total on Oct 28, 2026. Shares held after the trade: 442,560 (+46.7%).
Actuate Therapeutics closed an underwritten public offering of 30,985,900 shares of common stock and warrants to purchase 15,492,950 shares, raising gross proceeds of approximately $11.0 million. The offering was priced at $0.71 per set of two shares and one warrant, implying a per-share price of $0.355. The company intends to use the net proceeds for working capital and general corporate purposes.